Nachum Shamir Joins Stereotaxis’ Board of Directors

Stereotaxis has appointed Nachum “Homi” Shamir to its Board of Directors.

“We are delighted to have Homi join the Stereotaxis Board of Directors,” Stereotaxis Chairman/CEO David Fischel said. “Stereotaxis is blessed with a board that brings highly-relevant skillsets and complementary expertise as we advance an ambitious strategy. We look forward to benefiting from Homi’s contributions.”
 
Shamir most recently was chairman and CEO of Luminex Corporation from 2014 through its 2021 sale to DiaSorin S.p.A. for $1.8 billion. Before Luminex, Shamir was president and CEO of Given Imaging from 2006 through its 2014 sale to Covidien for $1 billion. He currently serves as chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnostica, a private-equity owned diagnostics company. Shamir has significant experience and expertise in growing global commercial organizations, scaling high-technology medical device operations, and successfully executing mergers and acquisitions.
 
“I am impressed by Stereotaxis’ comprehensive strategy and excited to join the company as it nears significant inflection points,” Shamir stated. “I look forward to contributing to the efforts to grow substantial global commercial and operational capabilities, and to the continued refinement of a strategy that will ensure robotics transforms endovascular surgery.”
 
Stereotaxis is a pioneer in innovative surgical robotics for minimally invasive endovascular intervention. It discovers, develops, and delivers robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat more than 100,000 patients across the United States, Europe, Asia, and elsewhere.